Martin Abraham Guiloff Salvador of Rani Therapeutics Holdings sold a total of 5,923,000 shares.

Filings Track

10/23

Martin Abraham Guiloff Salvador, a director of Rani Therapeutics Holdings, sold 1,923,000 and 4,000,000 shares of common stock on October 20 and October 21, 2025, respectively. Following these transactions, the total beneficially owned shares amount to 2,379,194. This significant disposal could signal concerns about the company's future prospects, warranting investor attention to market reactions.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1151619735"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151619735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151619735?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 07:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151619735","market":"us","top_or_hot":-1,"title":"Martin Abraham Guiloff Salvador of Rani Therapeutics Holdings sold a total of 5,923,000 shares.","media":"Filings Track","content":"Martin Abraham Guiloff Salvador, a director of Rani Therapeutics Holdings, sold 1,923,000 and 4,000,000 shares of common stock on October 20 and October 21, 2025, respectively. Following these transactions, the total beneficially owned shares amount to 2,379,194. This significant disposal could signal concerns about the company's future prospects, warranting investor attention to market reactions.","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Martin Abraham Guiloff Salvador of Rani Therapeutics Holdings sold a total of 5,923,000 shares.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMartin Abraham Guiloff Salvador of Rani Therapeutics Holdings sold a total of 5,923,000 shares.\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1033292654\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Filings Track </p>\n<p class=\"h-time smaller\">2025-10-23 07:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\nMartin Abraham Guiloff Salvador, a director of Rani Therapeutics Holdings, sold 1,923,000 and 4,000,000 shares of common stock on October 20 and October 21, 2025, respectively. Following these transactions, the total beneficially owned shares amount to 2,379,194. This significant disposal could signal concerns about the company's future prospects, warranting investor attention to market reactions.\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RANI","symbol_name":"Rani Therapeutics Holdings","start_time":0,"source_url":"","article_id":"1151619735","we_media_id":"1033292654","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151619735","pubTimestamp":1761174013,"columns":[{"name":"股东增减持","id":28,"label_key":"insiderTrades"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Filings Track","introduction":"Stay Updated with Major Exchanges' Announcements","home_visible":1,"id":"1033292654","head_image":"https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5"},"summary":"Martin Abraham Guiloff Salvador, a director of Rani Therapeutics Holdings, sold 1,923,000 and 4,000,000 shares of common stock on October 20 and October 21, 2025, respectively. Following these...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RANI":"Rani Therapeutics Holdings"},"translate_title":"Rani Therapeutics Holdings的Martin Abraham Guiloff Salvador总共出售了5,923,000股股票。","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RANI":1},"content_text":"Martin Abraham Guiloff Salvador, a director of Rani Therapeutics Holdings, sold 1,923,000 and 4,000,000 shares of common stock on October 20 and October 21, 2025, respectively. Following these transactions, the total beneficially owned shares amount to 2,379,194. This significant disposal could signal concerns about the company's future prospects, warranting investor attention to market reactions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"insiderTrades","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}